Physicians at the John Theurer Cancer Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics’s novel therapy, GDC-0084, for glioblastoma.  Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer, with limited available FDA-approved treatments and a median survival of only 15 months…